Positron Emission Tomography Using [<sup>18</sup>F]-Fluorodeoxy-<scp>d</scp>-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

Smith, Ian C. P.; Welch, Andrew; Hutcheon, A. W.; Miller, Iain D.; Payne, Simon; Chilcott, F.; Waikar, S.; Whitaker, Teena; Ah‐See, A. K.; Eremin, O.; Heys, Steven Darryll; Gilbert, Fiona J; Sharp, P.

doi:10.1200/jco.2000.18.8.1676

Cited by 395 publications

(201 citation statements)

References 51 publications

Supporting

Mentioning

181

Contrasting

Unclassified

Order By: Relevance

“…Using this criterion, 18 F-FDG PET/CT was found to have a sensitivity of 100%, a specificity of 85% and an accuracy of 88% in identifying responders after the first cycle, while corresponding values after the second cycle were 83%, 94% and 91% 8. After a single pulse of chemotherapy, 18 F-FDG PET was able to predict complete pathological response with a sensitivity of 90% and a specificity of 74% 9. The reported overall survival in 18 F-FDG PET/CT nonresponders is 8.8 months, compared with 19.2 months in responders 10.…”

Section: Methodsmentioning

confidence: 99%

¹⁸F-FDG PET/CT Imaging In Oncology

Almuhaideb

Παπαθανασίου

Bomanji

2011

Annals of Saudi Medicine

258

123

View full text Add to dashboard Cite

Accurate diagnosis and staging are essential for the optimal management of cancer patients. Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography (18F-FDG PET/CT) has emerged as a powerful imaging tool for the detection of various cancers. The combined acquisition of PET and CT has synergistic advantages over PET or CT alone and minimizes their individual limitations. It is a valuable tool for staging and restaging of some tumors and has an important role in the detection of recurrence in asymptomatic patients with rising tumor marker levels and patients with negative or equivocal findings on conventional imaging techniques. It also allows for monitoring response to therapy and permitting timely modification of therapeutic regimens. In about 27% of the patients, the course of managment is changed. This review provides guidance for oncologists/ radiotherapists and clinical and surgical specialists on the use of 18F-FDG PET/CT in oncology.

show abstract

Section: Methodsmentioning

confidence: 99%

¹⁸F-FDG PET/CT Imaging In Oncology

Almuhaideb

Παπαθανασίου

Bomanji

2011

Annals of Saudi Medicine

258

123

View full text Add to dashboard Cite

show abstract

“…Studies of cytotoxic chemotherapy in breast cancer, lymphoma, gastrointestinal cancers, and others indicated that FDG-PET is capable of detecting a response after a single cycle of chemotherapy. [33][34][35] In addition, in some lymphomas, significant changes in FDG uptake have been observed as early as 1 day after starting chemotherapy. 36 The reasons for the rapid decline in FDG uptake after cytotoxic chemotherapy are not known but are likely related to a decrease in the population of viable cells as well as a decrease in the rate of glycolysis per cell.…”

Section: Fdg-pet For Monitoring Tumor Responsementioning

confidence: 99%

PET/CT imaging in cancer: Current applications and future directions

Farwell

Pryma

Mankoff

2014

Cancer

185

120

View full text Add to dashboard Cite

Positron emission tomography (PET) is a radiotracer imaging method that yields quantitative images of regional in vivo biology and biochemistry. PET, now used in conjunction with computed tomography (CT) in PET/CT devices, has had its greatest impact to date on cancer and is now an important part of oncologic clinical practice and translational cancer research. In this review of current applications and future directions for PET/CT in cancer, the authors first highlight the basic principles of PET followed by a discussion of the biochemistry and current clinical applications of the most commonly used PET imaging agent, 18 F-fluorodeoxyglucose (FDG). Then, emerging methods for PET imaging of other biologic processes relevant to cancer are reviewed, including cellular proliferation, tumor hypoxia, apoptosis, amino acid and cell membrane metabolism, and imaging of tumor receptors and other tumor-specific gene products. The focus of the review is on methods in current clinical practice as well as those that have been translated to patients and are currently in clinical trials. Cancer 2014;120:3433-45.

show abstract

“…In a paper by Brock et al (2000) FDG PET measurements of MRGlu in brain tumours recorded at 7 days were found to be able to predict ultimate clinical and radiological response to chemotherapy recorded at 2 months. There is now published breast cancer data suggesting that this also may be true at other tumour sites (Smith et al 2000, Schelling et al 2000. The use of 18 F-FDG PET in the neoadjuvant setting may be very important -particularly for identifying non-responders early.…”

Section: Prediction Of Clinical Responsementioning

confidence: 99%

Changes in18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

Price

2000

Br J Cancer

View full text Add to dashboard Cite

There has been a lot of hype over the use of PET in oncology, with hopes that it will provide many answers in clinical research. However, now it has been brought to the attention of clinicians and oncology researchers, it is time to get down to the hard work of exploring its potential and defining its true role.In this edition of the BJC, a paper by Maisey et al (2000) explores the use of 18 F-FDG PET in predicting survival in patients with cancer of the pancreas following systemic chemotherapy. This is one in a series of similar papers that have been published by various groups over the last 4 or 5 years seeking to find the value of FDG PET in measuring response to therapy. So how far have we got? What PET isPositron emission tomography (PET) is a technique which uses radionuclides to label molecules. The molecules can then be imaged in man and this provides quantitative kinetic functional information. The inherent sensitivity and specificity of PET methodology is the most important strength of the technique. Its sensitivity is unrivalled and it can be used to image molecular interactions and pathways, providing quantitative kinetic information down to the sub-pico molar level (Jones, 1996). It lacks the spatial resolution of MRI or CT, but as it is unrivalled in its specificity and kinetic sensitivity, it has a huge future for translation research in oncology (Price, 1997).Molecular imaging using PET is now being developed to assess in vivo pharmacokinetics and pharmacodynamics in oncology (Young et al, 1999a;Saleem et al, 2000). However, currently few groups internationally have the range of expertise in radiochemistry, data analysis, bio-mathematical modelling and kinetic analysis to advance and exploit the technique for these purposes, so progress has been slow. PET methodology is better developed in neurology and psychiatry, but it is still in its infancy in oncology. Current diagnostic use of PETTo most of the oncology community, PET is understood to be static 18 F-FDG images of tumours. This is because the vast majority of work that has been performed in PET in oncology has been using 18 F-FDG. FDG (fluorodeoxyglucose) is an analogue of glucose which is taken up into cells by GLUT 1 transporters and trapped, as it is not metabolized by hexokinase. When FDG is labelled with fluorine-18, its kinetics can be imaged with PET and the resultant signal indicates glucose uptake and trapping. If static images are taken at a certain time (say 45 min post-injection) then images show hot-spots in tumours. Much of the work over the last 10 years has looked at the value of FDG as a diagnostic tool. This is on the basis that FDG is preferentially taken up into tumour cells and so from the differential uptake one can define malignant vs non-malignant disease. There are controversies in its use in diagnosis and to what extent it can replace conventional anatomical imaging (Price, 2000).Cameras for whole-body imaging have been developed in the last few years and so patient scanning can produce a 'soft tissue bone scan'....

show abstract

Positron Emission Tomography Using [¹⁸F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

Abstract: [(18)F]-FDG PET imaging of primary and metastatic breast cancer after a single pulse of chemotherapy may be of value in the prediction of pathologic treatment response.

Cited by 395 publications

References 51 publications

¹⁸F-FDG PET/CT Imaging In Oncology

¹⁸F-FDG PET/CT Imaging In Oncology

PET/CT imaging in cancer: Current applications and future directions

Changes in18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

Contact Info

Product

Resources

About

Positron Emission Tomography Using [18F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

Abstract: [(18)F]-FDG PET imaging of primary and metastatic breast cancer after a single pulse of chemotherapy may be of value in the prediction of pathologic treatment response.

Cited by 395 publications

References 51 publications

18F-FDG PET/CT Imaging In Oncology

18F-FDG PET/CT Imaging In Oncology

PET/CT imaging in cancer: Current applications and future directions

Changes in18F-FDG uptake measured by PET as a pharmacodynamic end-point in anticancer therapy. How far have we got?

Contact Info

Product

Resources

About

Positron Emission Tomography Using [¹⁸F]-Fluorodeoxy-d-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy

¹⁸F-FDG PET/CT Imaging In Oncology

¹⁸F-FDG PET/CT Imaging In Oncology